Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen T-VEC’s Remaining Challenges: Getting To Market, Staying Relevant

Executive Summary

After overwhelming but unenthusiastic endorsement from FDA’s advisory committee, the metastatic melanoma immunotherapy could still be hobbled by problematic trials as Amgen seeks approval path and prescriptions in rapidly changing disease space.

You may also be interested in...

INTERVIEW: SillaJen CEO Confident On ‘Dream’ Cancer Therapy (Pt. 2)

After years of convincing the medical industry about the value of its novel cancer immunotherapy, South Korea’s SillaJen may be stepping closer to its goal of commercializing the “dream cancer therapy.” The bioventure’s CEO, Moon Eun-sang, shares his views on the product and SillaJen’s future in this second and final part of an exclusive interview with PharmAsia News.

PD-1 Data Promise More Shake-ups In Melanoma Standard of Care

Studies presented at AACR highlight pros and cons of two new potential, competing frontline regimens in melanoma – Keytruda alone instead of Yervoy, or Yervoy in combination with Opdivo.

Novo Files Suit Over IRA As It Joins Others In Signing On To Price Negotiations

The nine drug manufacturers with products selected for Medicare drug price negotiations have agreed to participate in the program. Seven of them now have pending suits challenging the Inflation Reduction Act program with Novo’s recent complaint, which objects to the aggregation of its insulin products.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts